Lubreras Areta et al., Trends in preterm birth in women living with HIV in Switzerland
Trends in preterm birth in women living with HIV in Switzerland over the last three decades: A multicentric, prospective, cohort study. Â Â HIV Medicine Previous studies have shown that preterm birth is more common among pregnant women with HIV than among those without HIV. Several HIV-specific treatments may explain this: antiretroviral therapy can lead to early […]
Thoueille et al., Population pharmacokinetics of cabotegravir in real-world people with HIV
Population pharmacokinetics of cabotegravir following oral administration and long-acting intramuscular injection in real-world people with HIV. Clinical Pharmacology & Therapeutics Thoueille et al. aimed to characterize the concentration-time profile of long-acting cabotegravir and its associated variability among people with HIV (PWH) in the SHCS and therefore to build real-world reference percentile curves of cabotegravir concentrations that can […]
Pasin et al., Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities
Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities.  HIV Medicine Sex hormones play a crucial role in modulating the immune response. However, the effects of exogenous sex hormones – administered for contraception, menopause-related symptom management, or gender-affirming therapy – on HIV-related immune markers in people living with HIV are not […]
Byonanebye et al., Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving INSTI’s and TAF
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving INSTI’s and TAF.   Lancet HIV Byonanebye et al. on behalf of the RESPOND consortium aimed to compare the risk of new-onset hypertension or dyslipidaemia in people receiving integrase strand-transfer inhibitors (INSTIs), tenofovir alafenamide, or both versus regimens without INSTIs and tenofovir […]
Alvarez et al., Facteurs déterminants de la non-suppression virologique du VIH
La charge virale du VIH-1 et le nombre de cellules T CD4+ influencent l’efficacité des traitements à base d’inhibiteurs d’intégrase.   Clinical Infectious Diseases Bien que de nos jours, heureusement, peu de personnes vivant avec le VIH sous traitement antirétroviral (TAR) connaissent un échec thérapeutique, il n’est souvent pas évident d’en comprendre les raisons. Dans le […]
Alvarez et al., Fattori determinanti per la non soppressione virologica dell’HIV
La viremia HIV e il numero di linfociti CD4+ influenzano l’efficacia dei trattamenti con inibitori dell’integrasi.   Clinical Infectious Diseases Attualmente, per fortuna, solo poche persone che vivono con l’HIV sotto terapia antiretrovirale (ART) hanno un fallimento terapeutico e spesso non se ne comprendono facilmente i motivi. In passato una viremia elevata e un tasso di linfociti […]
Alvarez et al., Bestimmende Faktoren für die virologischen Nichtunterdrückung von HIV
Die Plasma-HIV-1-RNA und die Anzahl der CD4+-T-Zellen sind ausschlaggebend für die virologische Nichtunterdrückung bei der Erstbehandlung mit Integrase-Inhibitoren.   Clinical Infectious Diseases Auch wenn heutzutage glücklicherweise nur noch wenige Menschen mit HIV unter antiretroviraler Therapie (ART) ein Therapieversagen aufweisen, ist es oft nicht klar, die Gründe dafür zu verstehen. In der Vergangenheit wurden oft eine hohe […]
Fursa et al., SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among PLWH
SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort.   HIV Medicine Fursa et al. on behalf of the EuroSIDA cohort investigated SARS-CoV-2 testing positivity and hospital admissions in a large prospective cohort of people with HIV in Europe between 1 January 2020 and 31 December 2021 […]
Damas et al., Weight changes after discontinuing TAF
Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people living with Human Immunodeficiency Virus (HIV).  Clinical Infectious Diseases Managing obesity and cardiovascular disease has become an important aspect of clinical care in people with HIV (PWH). Concerns over antiretroviral therapy (ART) related weight gain, particularly with tenofovir alafenamide (TAF), prompted Damas […]
Weber et al., Death causes shift in the SHCS
Time trends in causes of death in people with human immunodeficiency virus: Insights from the Swiss HIV Cohort Study.  Clinical Infectious Diseases In their January 2024 article published in Clinical Infectious Diseases, Weber et al. analyzed the evolving causes of death among people living with HIV in the Swiss HIV Cohort Study over the past 17 years. The […]